Author/Authors :
TAJBAKHSH, Amir Department of Medical Genetics & Molecular Medicine - Faculty of Medicine - Mashhad University of Medical Sciences - Mash-had, Iran , FARJAMI, Zahra Department of Medical Genetics & Molecular Medicine - Faculty of Medicine - Mashhad University of Medical Sciences - Mash-had, Iran , NESAEI-BAJESTANI, Abolfazl Department of Basic Sciences - Faculty of Medicine - Gonabad University of Medical Sciences - Gonabad, Iran , AFZALJAVAN, Fahimeh Department of Medical Genetics & Molecular Medicine - Faculty of Medicine - Mashhad University of Medical Sciences - Mash-had, Iran , RIVANDI, Mahdi Department of Medical Genetics & Molecular Medicine - Faculty of Medicine - Mashhad University of Medical Sciences - Mash-had, Iran , MOEZZI, Atefeh Department of Medical Genetics & Molecular Medicine - Faculty of Medicine - Mashhad University of Medical Sciences - Mash-had, Iran , ABEDINI, Soheila Department of Medical Genetics & Molecular Medicine - Faculty of Medicine - Mashhad University of Medical Sciences - Mash-had, Iran , ASGHARI, Mahla Department of Medical Genetics & Molecular Medicine - Faculty of Medicine - Mashhad University of Medical Sciences - Mash-had, Iran , KOOSHYAR, Mohammad Mahdi Department of Hematology-Oncology - Imam Reza Hospital - Mashhad University of Medical Sciences - Mashhad, Iran , HOMAEI SHANDIZ, Fatemeh Mashhad University of Medical University, Mashhad, Iran , PASDAR, Alireza Mashhad University of Medical University, Mashhad, Iran
Abstract :
Background: CC chemokine receptor 5 (CCR5) is introduced as an immune response modulator. The activi-ty of CCR5 influences breast tumour development in a p53-dependent manner. This study aimed to investigate the frequency of CCR5delta32 and its association with the risk of breast cancer in 1038 blood samples in North East of Iran.
Methods: In this case-control study, we genotyped 570 control samples and 468 breast cancer patients by a gel electrophoresis-based gap-polymerase chain reaction (gap-PCR) method Mashhad, Iran. The data were analyzed using the SPSS software.
Results: Of 570 controls included, 542 (95.09%) had CCR5delta32 wild/wild (W/W) genotype, 28 samples (4.91%) had CCR5delta32 wild/deletion (W/D) genotype and none of them were CCR5delta32 deletion/deletion (D/D) genotype (0%). While 428 samples of patients (91.45%) had CCR5delta32 W/W genotype, 40 samples (8.55%) had CCR5delta32 W/D and CCR5delta32 D/D homozygous was nil (0%) amongst cases. All samples were in the Hardy–Weinberg equilibrium (P>0.05). According to the allele frequency, D allele, as a risky allele, in the cases was more than the control samples (0.0427 vs 0.0245, respectively) (P=0.0206). Hence, W/D genotype may confer a risk ef-fect (OR=1.77, CI: 1.09-2.90; P=0.0206) compared with WW genotype between case and control groups.
Conclusion: There is a statistically significant association between CCR5W/D and breast cancer risk. CCR5 may be regarded as a target for the prevention of breast cancer in certain conditions such as interaction with p53 variants, which remains to be further investigated.
Keywords :
CCR5D32 , p53 pathway , Breast carcinoma , Immunogenetics , Metastasis
